Abstract
Ferroptosis, a form of regulated cell death associated with iron-dependent lipid peroxidation, can be induced in cultured cells by chemicals such as erastin and RSL3. Protein disulfide isomerase (PDI) has been identified as a mediator of chemically-induced ferroptosis and a crucial target for protection. This study reports that bazedoxifene (BAZ), a selective estrogen receptor modulator, acts as an inhibitor of PDI and provides strong protection against ferroptosis in neuronal cells. BAZ directly binds to PDI, inhibiting its catalytic activity through a hydrogen bond with the His256 residue. This inhibition reduces iNOS and nNOS dimerization, nitric oxide (NO) accumulation, and cellular reactive oxygen species (ROS), including lipid-ROS. In vivo experiments demonstrate that BAZ protects mice against kainic acid-induced memory deficits and hippocampal damage, suggesting an estrogen receptor-independent, PDI-mediated neuroprotective mechanism.
Introduction: The Challenge of Ferroptosis
Ferroptosis is a regulated cell death pathway driven by iron-dependent lipid peroxidation. It is increasingly recognized as a significant factor in neurodegenerative diseases like Alzheimer’s and Parkinson’s, as well as ischemic injuries such as stroke. Consequently, identifying pharmacological inhibitors of ferroptosis is a high priority in neuropharmacology.
Bazedoxifene (BAZ) is an FDA-approved Selective Estrogen Receptor Modulator (SERM) currently used to treat postmenopausal osteoporosis. While SERMs have shown neuroprotective potential, the underlying molecular mechanisms—especially those independent of estrogen receptors—have remained unclear. This research investigates BAZ's ability to prevent ferroptosis by targeting specific cellular pathways.
Methodology and Target Identification
The study employed a multi-disciplinary approach, including in vitro cell biology, biophysical assays, computational modeling, and in vivo behavioral testing. Researchers used HT22 mouse hippocampal neuronal cells treated with erastin and RSL3 to model ferroptosis.
To confirm the molecular changes associated with ferroptosis and BAZ treatment at the transcriptional level, RT-qPCR was performed on key regulatory genes, including markers of lipid metabolism and antioxidant response.
Target identification involved Surface Plasmon Resonance (SPR) and Cellular Thermal Shift Assays (CETSA) to characterize the binding between BAZ and PDI. Molecular docking and 100-ns Molecular Dynamics (MD) simulations were used to map the binding pocket, specifically identifying the role of the His256 residue.
Key Insights: A Novel Mechanism of Action
The study revealed that BAZ's neuroprotective effect is mediated through direct binding to Protein Disulfide Isomerase (PDI). While PDI typically assists in protein folding, under oxidative stress, it can facilitate cell death pathways.
- The His256 Interaction: Simulations showed BAZ forms a critical hydrogen bond with PDI’s His256 residue. Mutating this residue (His256 to Ala256) abolished BAZ's inhibitory effect, confirming the binding site.
- ER-Independent Protection: BAZ remained effective in cells lacking estrogen receptors (e.g., MDA-MB-231), proving the mechanism is distinct from its primary pharmacological use in bone health.
- Disrupting the Toxic Cascade: By inhibiting PDI, BAZ prevents the dimerization of Nitric Oxide Synthase (NOS), thereby reducing toxic NO and lipid-ROS accumulation.
Results: Potent Neuroprotection
- In Vitro Efficacy: BAZ achieved 100% protection against erastin-induced death at 500 nM and against RSL3-induced death at 125 nM.
- High Binding Affinity: SPR assays calculated a $K_d$ of 3.3–3.6 nM for the BAZ-PDI interaction.
- In Vivo Rescue: In a kainic acid-induced injury model, 3 mg/kg BAZ significantly improved working memory in mice, increasing Y-maze alternation rates from ~50% (random performance) to 65.5%.
- Tissue Preservation: Histological analysis showed a dramatic reduction in degenerating neurons in the hippocampal CA3 region, from 124.3 ± 17.5 to 32.3 ± 8.7 per field.
Conclusion
Bazedoxifene emerges as a potent PDI inhibitor capable of halting ferroptosis in neurons. This discovery highlights an estrogen receptor-independent pathway for neuroprotection, positioning BAZ as a promising candidate for repurposing in the treatment of neurodegenerative disorders. Future research may explore the broader clinical implications of PDI inhibition, including its role in lipid metabolism and cholesterol management.
Summary updated